论文部分内容阅读
目的观察参芪口服液联合治疗儿童反复呼吸道感染的疗效及对机体免疫功能的影响。方法选取反复呼吸道感染患儿80例,按随机数字表法分为参芪组和对照组,每组40例。两组均给予抗感染、对症等常规治疗,参芪组在常规治疗的基础上再加用参芪口服液8周,随访12个月,治疗结束后观察患儿症状改善情况,检测T细胞亚群和免疫球蛋白,进行两组临床疗效评判。结果参芪组总有效率优于对照组(92.5%vs.82.5%,P<0.05),参芪组咳嗽消失时间、扁桃体肿大消退时间、肺部啰音消失时间较对照组短(P<0.05),参芪组治疗后免疫球蛋白(IgA、IgG、IgM)及T细胞亚群(CD3+、CD4+、CD8+)均高于对照组(P<0.05)。结论参芪口服液治疗儿童反复呼吸道感染能缓解急性发作期的症状与体征,增强患儿细胞免疫及体液免疫功能,值得临床使用。
Objective To observe the curative effect of Shenqi Oral Liquid in treating recurrent respiratory tract infections in children and its effect on immune function. Methods Eighty children with recurrent respiratory tract infection were selected and randomly divided into Shenqi group and control group with 40 cases in each group. Both groups were given anti-infection, symptomatic and other conventional treatment, Shenqi group on the basis of conventional treatment plus Shenqi oral solution for 8 weeks, followed up for 12 months, after treatment to observe the symptoms of children with improvement, detection of T cells Group and immunoglobulin, two sets of clinical efficacy evaluation. Results The total effective rate of Shenqi group was significantly higher than that of the control group (92.5% vs 82.5%, P <0.05), and the disappearance time of cough, the disappearance of tonsil and the disappearance of pulmonary rales in the Shenqi group were shorter than those in the control group (P < 0.05). Immunoglobulin (IgA, IgG, IgM) and T lymphocyte subsets (CD3 +, CD4 +, CD8 +) in Shenqi group were higher than those in control group after treatment (P <0.05). Conclusion Shenqi oral liquid in children with recurrent respiratory infections can relieve the symptoms and signs of acute exacerbation, and enhance cellular immunity and humoral immune function in children worthy of clinical use.